BlackRock’s Regencell Bioscience RGC Stock Holding History

BlackRock’s Portfolio RGC Stock Details RGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30K	Sell	4,925 -32	-0.6%	-$769	﹤0.01%	5292
2026 Q1	$126K	Buy	4,957 +92	+2%	+$2.6K	﹤0.01%	4911
2025 Q4	$102K	Hold	4,865	–	–	﹤0.01%	4901
2025 Q3	$75.2K	Sell	4,865 -3,724	-43%	-$53.4K	﹤0.01%	4905
2025 Q2	$146K	Sell	8,589 -5,205	-38%	-$63.5K	﹤0.01%	4746
2025 Q1	$11.6K	Buy	13,794 +4,750	+53%	+$1.31K	﹤0.01%	5164
2024 Q4	$1.18K	Hold	9,044	–	–	﹤0.01%	5303
2024 Q3	$1.32K	Hold	9,044	–	–	﹤0.01%	5127
2024 Q2	$800	Hold	9,044	–	–	﹤0.01%	5211
2024 Q1	$1.07K	Hold	9,044	–	–	﹤0.01%	5201
2023 Q4	$2.5K	Hold	9,044	–	–	﹤0.01%	5232
2023 Q3	$3.33K	Hold	9,044	–	–	﹤0.01%	5271
2023 Q2	$5.17K	Hold	9,044	–	–	﹤0.01%	5310
2023 Q1	$6.16K	Hold	9,044	–	–	﹤0.01%	5361
2022 Q4	$6.47K	Hold	9,044	–	–	﹤0.01%	5501
2022 Q3	$8K	Hold	9,044	–	–	﹤0.01%	5603
2022 Q2	$8K	Buy	+9,044	New	+$6.82K	﹤0.01%	5646

Other funds holding RGC

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

BlackRock's RGC Position: Q2 2026 in Review

BlackRock reduced its Regencell Bioscience (RGC) stake by 0.65% in Q2 2026, selling an estimated $769 and leaving 4,925 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #5292.

BlackRock first reported a position in RGC in Q2 2022 and has held it in 17 quarters since. The position peaked at $146K in Q2 2025. 35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

BlackRock held 4,925 shares of Regencell Bioscience worth $30K as of Q2 2026.
BlackRock sold 32 Regencell Bioscience shares in Q2 2026, an estimated $769.
Regencell Bioscience made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5292 holding.
BlackRock first reported a position in Regencell Bioscience in Q2 2022 and has held it in 17 quarters since.
BlackRock's Regencell Bioscience position peaked at $146K in Q2 2025.
35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.